4th Bioequivalence Summit 2017

Topics

• Advances in FDA regulations and requirements for ANDAs and biosimilars
• Innovative testing and modeling procedures that cut cost and provide more accurate results
• Legal challenges from originator drug companies that impact the development of biosimilars
• Highly demanded alternative delivery methods, such as long-acting injectables and topical applications
• The latest in current drug development issues, such as oncology and abuse-detterant innovation

Who should Attend

Attendees with responsibilities in:

• Pharmaceutics/Biopharmaceutics
• Pharmacokinetics/Pharmacodynamics/Drug Metabolism/PKDM
• Drug Delivery
• Drug Discovery
• Formulation
• Preclinical Research
• Biostatistics
• Preformulation
• Life Cycle Management